Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase
- PMID: 9721601
- DOI: 10.1006/phrs.1998.0345
Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase
Abstract
A marked and sustained bronchoconstriction after antigen challenge was produced in actively sensitised guinea pigs, and correlated with increments of thromboxane (TX) A2 level in both the plasma and bronchoalveolar lavage fluid. DP-1904 given orally relieved the bronchoconstriction and increase in TXA2 in a dose-dependent manner. In platelet-depleted animals, antigen-induced bronchoconstriction and TXA2 release in the plasma were significantly reduced compared to those of non-platelet-depleted animals, indicating that platelets are a major cell source of TXA2 production, the remainder originating from the other cells excluding platelets. In the platelet-deprived animal, DP-1904 showed further significant inhibition of the constriction and plasma TXA2 level, and therefore likely inhibits TXA2 synthesis of various cells, including platelets, in the bloodstream. The results suggested that TXA2 is an important mediator responsible for producing antigen-induced bronchoconstriction, and endogenously originated from various cells including platelets in guinea pigs.
Similar articles
-
In vitro effect of DP-1904, a novel anti-asthma agent, against antigen-induced constriction and TXB2 release from the isolated guinea-pig lung parenchymal tissue.Pharmacol Res. 1998 Aug;38(2):141-7. doi: 10.1006/phrs.1998.0346. Pharmacol Res. 1998. PMID: 9721602
-
Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.J Pharmacol Exp Ther. 1992 Feb;260(2):832-40. J Pharmacol Exp Ther. 1992. PMID: 1738127
-
Inhibitory effect of thromboxane A2 synthetase inhibitor, DP-1904, on antigen-induced contraction of human lung parenchyma.Ann Allergy Asthma Immunol. 1996 Dec;77(6):483-7. doi: 10.1016/S1081-1206(10)63355-8. Ann Allergy Asthma Immunol. 1996. PMID: 8970439
-
Overview of physiological and pathophysiological effects of thromboxane A2.Fed Proc. 1987 Jan;46(1):133-8. Fed Proc. 1987. PMID: 2948837 Review.
-
Biosynthesis and pharmacological modulation of thromboxane in humans.Circulation. 1990 Jan;81(1 Suppl):I12-5; discussion I22-3. Circulation. 1990. PMID: 2136814 Review.
Cited by
-
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.Front Immunol. 2021 Jun 25;12:695815. doi: 10.3389/fimmu.2021.695815. eCollection 2021. Front Immunol. 2021. PMID: 34305932 Free PMC article. Review.
-
Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease.World J Otorhinolaryngol Head Neck Surg. 2018 Sep 5;4(3):162-168. doi: 10.1016/j.wjorl.2018.08.001. eCollection 2018 Sep. World J Otorhinolaryngol Head Neck Surg. 2018. PMID: 30506046 Free PMC article. Review.
-
Platelets in patients with aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2015 Jun;135(6):1407-14; quiz 1415. doi: 10.1016/j.jaci.2015.02.005. J Allergy Clin Immunol. 2015. PMID: 26051947 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
